A pilot study conducted by Vaaji in collaboration with the Penn Artificial Intelligence and Technology Collaboratory (PennAITech) at the University of Pennsylvania has demonstrated 100% technical accuracy in monitoring transdermal patch status. The study, part of the AI/Tech + Aging (A2) Collective funded by the National Institute on Aging (NIA), validates the smart patch system as a potential tool to significantly improve safety in medication delivery.
This development addresses a critical safety gap, as transdermal patches are commonly used for medications treating Alzheimer's, Parkinson's, and pain management, where errors like applying a new patch without removing the old one can lead to ineffective treatment or life-threatening overdoses. The proof-of-concept study enrolled 51 healthy volunteers using placebo patches to evaluate the system's detection capabilities against manual oversight. The results showed perfect correlation between Vaaji's remote monitoring data and site investigator records, matching the gold standard of direct human supervision.
The system successfully identified simulated patch stacking in real-time, validating the core technology required to prevent overdose events in future clinical applications. Furthermore, the technology integrated smoothly into volunteers' daily routines, supporting its feasibility for home-based care. Patrick Mercier, Professor of Electrical and Computer Engineering at UCSD and Chief Technical Advisor at Vaaji, stated that this study provides the first real-world evidence that the smart patch platform can deliver perfect accuracy in detecting patch application errors.
William Z. Potter, MD, PhD, co-Principal Investigator and Chief Scientific Advisor at Vaaji, noted that the 100% agreement between remote monitoring and site investigator records is a landmark result, demonstrating the system's potential to match human oversight for safer home care solutions. Sandeep Patil, MD, PhD, Co-founder of Vaaji, emphasized the growing need for technologies that enable safe, independent living as the aging population increases.
The data from this pilot study will inform Vaaji's clinical and regulatory strategy as the company advances toward broader clinical trials involving active therapeutics. The company aims to establish its smart monitoring platform as a new safety standard for high-risk transdermal medications. The project is supported by the National Institute on Aging of the National Institutes of Health under Award Number 1-P30-AG-073105-01. For more information on Vaaji's patient-centric platform, visit Vaaji.
